FDA
-
-
-
-
-
-
-
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
-
-
-
-
-
-
-
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
-
-
-
-
-
-
-
Finch Therapeutics (FNCH) Announces Removal of FDA Clinical Hold on CP101 IND
-
-
-
-
-
-
-
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Finch Therapeutics Announces Additions to Senior Leadership Team
-
-
-
-
-
-
-
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
-
322,095 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

